Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 226 to 240 of 371 results for hypertension

  1. Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

    Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.

  2. Alcohol-use disorders: prevention (PH24)

    This guideline covers alcohol problems among people over 10. It aims to prevent and identify such problems as early as possible using a mix of policy and practice.

  3. Older people with social care needs and multiple long-term conditions (NG22)

    This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.

  4. Weight management: obesity register (IND238)

    This indicator covers the establishing and maintaining of a register of patients aged 18 or over with a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM222

  5. Weight management: overweight register (IND237)

    This indicator covers the establishing and maintaining of a register of patients aged 18 or over with a BMI of 23 kg/m2 or more (or 25 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM221

  6. Hypertension in pregnancy: diagnosis and management (CG107)

    This guidance has been updated and replaced by NICE guideline NG133

  7. Hypertension in adults: diagnosis and management (CG127)

    This guidance has been updated and replaced by NICE guideline NG136.

  8. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MIB174)

    NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .

  9. Tirzepatide for managing overweight and obesity (TA1026)

    Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.

  10. The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)

    NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .

  11. Icare rebound tonometer to measure intraocular pressure (MIB57)

    NICE has developed a medtech innovation briefing (MIB) on the Icare rebound tonometer to measure intraocular pressure

  12. Butterfly iQ+ for diagnostic ultrasound imaging (MIB254)

    NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .

  13. Naltrexone–bupropion for managing overweight and obesity (TA494)

    Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.

  14. Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

    Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.

  15. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.